RA Capital Management as of March 31, 2011
Portfolio Holdings for RA Capital Management
RA Capital Management holds 27 positions in its portfolio as reported in the March 2011 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sequenom | 10.3 | $16M | 2.5M | 6.34 | |
| Pharmasset | 7.7 | $12M | 148k | 78.71 | |
| Targacept | 7.0 | $11M | 403k | 26.59 | |
| Valeant Pharmaceuticals Int | 6.9 | $11M | 212k | 49.81 | |
| Alexion Pharmaceuticals | 6.6 | $10M | 101k | 98.68 | |
| Affymax (AFFY) | 6.5 | $9.8M | 1.7M | 5.87 | |
| ArthroCare Corporation | 6.4 | $9.7M | 290k | 33.34 | |
| ACADIA Pharmaceuticals (ACAD) | 5.5 | $8.4M | 5.2M | 1.62 | |
| OncoGenex Pharmaceuticals | 5.3 | $8.1M | 528k | 15.30 | |
| Gilead Sciences (GILD) | 5.3 | $8.1M | 190k | 42.47 | |
| United Therapeutics Corporation (UTHR) | 4.5 | $6.9M | 103k | 67.02 | |
| Jazz Pharmaceuticals | 4.5 | $6.9M | 215k | 31.85 | |
| Dynavax Technologies Corporation | 4.0 | $6.0M | 2.2M | 2.76 | |
| BioSpecifics Technologies | 3.9 | $6.0M | 234k | 25.50 | |
| ADVENTRX Pharmaceuticals | 3.3 | $5.0M | 2.4M | 2.10 | |
| Columbia Laboratories | 2.7 | $4.1M | 1.1M | 3.77 | |
| Repligen Corporation (RGEN) | 2.2 | $3.3M | 890k | 3.74 | |
| Tengion (TNGN) | 1.7 | $2.6M | 1.1M | 2.49 | |
| Endocyte | 1.4 | $2.0M | 239k | 8.57 | |
| Inhibitex | 0.7 | $1.1M | 301k | 3.62 | |
| Discovery Laboratories | 0.7 | $1.1M | 575k | 1.85 | |
| Maxygen | 0.6 | $926k | 178k | 5.20 | |
| Oncothyreon | 0.6 | $916k | 237k | 3.87 | |
| ArQule | 0.5 | $815k | 114k | 7.14 | |
| Enzo Biochem (ENZ) | 0.5 | $787k | 188k | 4.19 | |
| Opko Health (OPK) | 0.4 | $560k | 150k | 3.73 | |
| Derma Sciences | 0.3 | $436k | 45k | 9.70 |
